 |
PDBsum entry 3dtc
|
|
|
|
References listed in PDB file
|
 |
|
Key reference
|
 |
|
Title
|
 |
Mixed-Lineage kinase 1 and mixed-Lineage kinase 3 subtype-Selective dihydronaphthyl[3,4-A]pyrrolo[3,4-C]carbazole-5-Ones: optimization, Mixed-Lineage kinase 1 crystallography, And oral in vivo activity in 1-Methyl-4-Phenyltetrahydropyridine models.
|
 |
|
Authors
|
 |
R.L.Hudkins,
J.L.Diebold,
M.Tao,
K.A.Josef,
C.H.Park,
T.S.Angeles,
L.D.Aimone,
J.Husten,
M.A.Ator,
S.L.Meyer,
B.P.Holskin,
J.T.Durkin,
A.A.Fedorov,
E.V.Fedorov,
S.C.Almo,
J.R.Mathiasen,
D.Bozyczko-Coyne,
M.S.Saporito,
R.W.Scott,
J.P.Mallamo.
|
 |
|
Ref.
|
 |
J Med Chem, 2008,
51,
5680-5689.
|
 |
|
PubMed id
|
 |
|
 |
 |
|
Abstract
|
 |
|
The optimization of the dihydronaphthyl[3,4-a]pyrrolo[3,4-c]carbazole-5-one R(2)
and R(12) positions led to the identification of the first MLK1 and MLK3
subtype-selective inhibitors within the MLK family. Compounds 14 (CEP-5104) and
16 (CEP-6331) displayed good potency for MLK1 and MLK3 inhibition with a greater
than 30- to 100-fold selectivity for related family members MLK2 and DLK.
Compounds 14 and 16 were orally active in vivo in a mouse MPTP biochemical
efficacy model that was comparable to the first-generation pan-MLK inhibitor 1
(CEP-1347). The MLK1 structure-activity relationships were supported by the
first-reported X-ray crystal structure of MLK1 bound with 16.
|
 |
|
|
|
|
 |